The aim of this study was to determine whether daily increasing doses of hCG could overcome luteal regression induced by PGF2\g=a\ in rhesus monkeys. Prostaglandin F2\ g=a\ (10 ng \g=m\l \ m=-\ 1 h\m=-\1) or vehicle (tham buffer; 1 \ g=m\ l h \ m= -\ 1 ) was infused directly into the corpus luteum for 7 days, beginning 7 days after the preovulatory oestradiol surge. hCG was injected i.m. in increasing doses (15, 30, 60, 90, 180, 360 and 720 iu) for 7 days, starting on the eighth day after the preovulatory oestradiol surge, or 1 day after the initiation of luteal infusion of PGF2\g=a\ or vehicle. Monkeys receiving vehicle plus hCG on the same days served as controls. Daily progesterone, oestradiol and hCG concentrations were determined from blood drawn from the saphenous or femoral vein, and the duration of the luteal phases were recorded. Where intraluteally infused PGF2\g=a\ resulted in premature, functional luteolysis, hCG always inhibited the luteolytic effect of PGF2\g=a\; the secretory patterns of progesterone and oestradiol were augmented, and peak values were reached in concert with the highest concentration of hCG in the blood, and the luteal phase was significantly increased compared with those of untreated monkeys or with monkeys treated with PGF2\g=a\ alone or vehicle. Treatment with hCG alone or with PGF2\g=a\ vehicle also resulted in maintained luteal function and a significantly longer luteal phase, but both progesterone and oestradiol concentrations began to decline before hCG reached peak values in the circulation. Once the hCG regimen was concluded, luteal regression ensued and menses occurred at a time coincident with decreased steroid endometrial support. These results are the first to show that hCG can inhibit luteal regression induced by PGF2\g=a\ in vivo, and are contrary to results obtained in vitro using minced or sliced luteal cells, which indicates that PGF2\g=a\ inhibits the trophic action of LH or hCG on progesterone secretion. We conclude that in the rhesus monkey, hCG can completely abolish the luteolytic effect of PGF2\g=a\through an unknown mechanism. studies in vivo and in vitro into account, it appears that for
Introduction
Prostaglandin F2a (PGFM) has been shown to be luteolytic when infused at physiological doses directly into the corpus luteum of rhesus monkeys (Auletta et al, 1984a;  Zelinski-Wooten and Stouffer, 1990) . Similarly, several studies in women have shown that transient reductions in circulating progesterone concentrations occur after systemic (Wentz and Jones, 1973) and intraluteal (Korda et al, 1975) administration of pharmaco¬ logical doses of PGF2". PGF2(1 analogues also induce luteolysis in early-pregnant rhesus monkeys (Wilks, 1980) and marmosets (Summers et al, 1985) . Finally, the concentration of the major blood metabolite of PGF2a, 13,14-dihydro-15-keto-PGF2cl , is significantly increased in the monkey ovarian effluent on the corpus luteum side compared with the contralat¬ eral effluent during luteal regression (Auletta et al, 1984b) .
Collectively, these studies show that PGF2(I is luteolytic in primates and supports a role for PGF2a in regulating luteal function.
Investigations in vitro using minced or dispersed luteal cells from a variety of nonprimate (Behrman and Hichens, 1976; Auletta and Flint, 1988) and primate species (Richardson, 1986;  Auletta, 1990; Patton and Stouffer, 1991) have produced conflicting results. Whereas a consistent antigonadotrophic action of PGF2(1 on progesterone concentrations increased by LH or hCG has been observed in minced cell or slice preparations, it has been shown that PGF2(I stimulates pro¬ gesterone production in dispersed luteal cells from earlyand mid-pregnant (but not late-pregnant) rhesus monkeys (Stouffer et al, 1979) , and enhances hCG-stimulated progesterone secre¬ tion in dispersed human luteal cells (Richardson and Masson, 1980) and cloprostenol-treated dispersed marmoset luteal cells (Michael et al, 1993) . Taking these conflicting results from PGF2a to have a consistent antigonadotrophic action, the integrity and age of the corpus luteum are vital.
In rhesus monkeys, the observations that chorionic gonado¬ trophin can rescue the corpus luteum (Wilks and Noble, 1983) , that immunization against hCG blocks maintenance of preg¬ nancy (Moudgal et al, 1971) , and that the concentration of chorionic gonadotrophin doubles every 48 h during early pregnancy (Atkinson et al, 1975) emphasize the importance of this steroid.
Taken together, these observations support a role for both PGF2a and hCG in the demise and maintenance of the corpus luteum. Because of the conflicting results in vitro, the objective of the present study was to determine whether increasing daily doses of hCG could inhibit the luteolytic action of luteally infused PGF2a in vivo.
Materials and Methods

Animals
Adult female rhesus monkeys (Macaca mulatta) with regular menstrual cycles were used in this study. The monkeys were housed individually under artificially controlled conditions of illumination (from 06:00 h to 18:00 h), temperature (20°C) and humidity (30%). They were fed commercially prepared monkey chow supplemented with fresh fruit. Water was always avail¬ able. Daily morning vaginal inspection and lavage were performed to detect the onset and duration of menstrual bleeding. The first day of menses was designated day 1 of the menstrual cycle.
Ethics of experimentation
This investigation was approved by the University of Vermont Institutional Animal Care and Use Committee in accordance with all applicable federal and state laws and regulations.
Blood sampling and hormone assays
During the treatment cycles, peripheral blood (2-3 ml) was drawn from either the saphenous or femoral vein once a day to determine the day of the preovulatory oestradiol surge; this day was defined as day 0. All blood samples were collected into heparinized tubes between 07:00 h and 10:00 h, and the plasma was frozen ( -20°C) until the oestradiol and pro¬ gesterone concentrations were measured by radioimmunoassay and the hCG concentration was measured by fluoroimmunoassay, as described by Auletta et al (1984a) and Nakajima et al (1990) . Briefly, the steroids were assayed in at least duplicate using radioimmunoassay kits supplied by Leeco Diagnostics (Southfield, MI) . Similarly, hCG was determined in triplicate using immunofluorescence kits purchased from Pharmacia-ENI Diagnostic, Inc. (Columbia, MA); this method involves a solid two-site sandwich assay calibrated against the WHO First International Reference Preparation (IRP 75/537). Intra-assay and interassay coefficients of variation were 4.3% and 5.8% for hCG, 3.7% and 7.6% for progesterone, and 5.3% and 8.7% for oestradiol, respectively. Blood samples were always collected before hCG injections. The duration of the cycle, luteal phase and the onset of menses from the initiation of treatment were recorded.
Surgical model
PGF2(1 or its vehicle was delivered to the corpus luteum using an Alzet pump-luteal cannula system (Auletta et al, 1984a) . Under sterile conditions, a mid-ventral laparotomy was performed under sodium pentobarbital (20 mg kg~b ody mass) anaesthesia (Park Davis, St Louis, MO), and the ovary bearing the corpus luteum was identified. The ovarian capsule adjacent to the corpus luteum was punctured with an 18-gauge needle and a polyvinyl no. 2 cannula connected to an Alzet osmotic pump (Model 2001; Alza Corporation, Palo Alto, CA) was inserted through the adjacent stroma directly into the corpus luteum and secured. Before the pump was closed, it was exteriorized in the subcutaneous flank. The cannula and pump were prefilled. The pump is designed to deliver 1 µ solute hf or 7 days (170 µ volume capacity).
Experimental design
Monkeys were infused intraluteally for 7 days with 10 ng PGF2a µ ~* h~I or 1 µ vehicle h~* [tris hydroxymethyl aminomethane (tham) buffer], both purchased from Sigma Chemical Co. (St Louis, MO) from day 7 after the preovulatory oestradiol surge. hCG (Sigma Chemical Co.) was injected i.m. in increasing doses of 15, 30, 60, 90, 180, 360 and 720 iu, as modified from the method of Wilks and Noble (1983) , starting 8 days after the preovulatory oestradiol surge or 1 day after the initiation of luteal PGF2Q or vehicle infusion. There were five experimental groups: (1) PGF2a; (2) PGF2a vehicle; (3) hCG; (4) PGF2" vehicle plus hCG; and (5) PGF2a plus hCG.
Statistical analyses
Results are expressed as means ± sem. Serial hormone data were assessed using one-way analysis of variance (anova) with repeated measures. Differences in the intervals of the cycle were also resolved by anova (Steel and Torrie, 1960).
Probabilities of < 0.05 were accepted as significant.
Results
PGF2a and PGF2a vehicle
In animals given PGF2a, both progesterone (P<0.01) and oestradiol (P < 0.05) concentrations decreased significantly after 1 day of exposure, and continued declining until menses (Fig. 1 ). Animals given vehicle displayed normal patterns of steroid concentrations. PGF2(J infusion resulted in premature luteolysis (Table 1) . hCG hCG always rescued the corpus luteum, as shown by the significant increase in progesterone concentration after the first E 6. cValue is significantly shorter compared with other treatments (P < 0.01).
Value is significantly longer compared with treatment with prostaglandin F2( (PGF2J or vehicle (P< 0.01).
hCG injection (Fig. 2) ; the progesterone concentration remained high during the treatment regimen. Oestradiol was also stimulated by hCG, but the pattern was less pronounced than was the progesterone response. There was a significant lengthening of the luteal phase compared with those of untreated monkeys or with monkeys treated with PGF2o or vehicle (Table 1) .
hCG plus PGF2a vehicle hCG rescued the corpus luteum under these conditions (Fig. 3 ). Although the response of both progesterone and oestradiol to hCG was initially blunted, the concentrations of both steroids increased significantly during hCG stimulation. There was also a significant increase in progesterone and Results are expressed as means ± sem. The plasma volume of the adult female rhesus monkey is approximately 400-600 ml (n = 5). 1st IRP:
First International Reference Preparation. oestradiol concentrations on days 11-14 compared with treat¬ ment with hCG alone. The duration of the luteal phase was significantly longer than when PGF2cl or vehicle was infused, but was similar to that when hCG was infused alone (Table 1) . hCG plus PGF2a hCG always inhibited the luteolytic action of intraluteally infused PGF2u (Fig. 4) . After exposure to PGF2a for 1 day, the concentration of progesterone significantly declined; hCG caused a significant stimulation of progesterone, which reached a plateau during hCG exposure; a similar result was obtained for oestradiol. Progesterone and oestradiol concen¬ trations remained high until hCG support was withdrawn. As in the group treated with hCG plus PGF2a vehicle, there was a significant increase in progesterone and oestradiol on days 12-15 compared with that after treatment with hCG alone. The luteal phase and the time to the onset of menses were significantly increased compared with those of monkeys treated with PGF2a, vehicle, or untreated monkeys (Table 1) .
Discussion
It has been proposed that PGF2a of ovarian origin represents the physiological luteolysin in primates (Auletta, 1990; Abayasekara el al, 1993; Michael et al, 1994) . However, how PGF2a causes luteal demise is unknown. Studies from this laboratory were the first to show that infusion of PGF2(I directly into the corpus luteum in vivo at a physiological rate results in premature luteal regression (Auletta et al, 1984a) . Similar observations in vivo have been made in other primates (Summers et al, 1985; Hearn and Webley, 1987;  Zelinski- Wooten and Stouffer, 1990) . In attempts to ascertain the mechanism of PGF2a action, studies of whole-cell preparations in vitro consistently demonstrated that it inhibited LHor hCG-stimulated progesterone production (Behrman and Hichens, 1976; Auletta and Flint, 1988; Patton and Stouffer, 1991; Michael et al, 1994) . Conflicting results have been observed in studies using dispersed luteal cells of the monkey (Stouffer et al, 1977 (Stouffer et al, , 1979 , human (Richardson and Masson, 1980; Webley et al, 1991) and marmoset (the marmoset cells were pretreated with hCG or LH before treatment with cloprostenol, a PGF2a analogue; Michael and Webley, 1991) . The observed inhibitory action has been postulated to occur via decreased gonadotrophin binding, receptor loss and post-cAMP-mediated steroidogenic events (Jordan, 1981; Kenny and Robinson, 1986; Michael and Webley, 1991; Abayasekara et al, 1993) .
In the study reported here, we confirmed earlier obser¬ vations that intraluteally infused PGF2o causes premature luteal regression (Auletta et al, 1984a; Zelinski-Wooten and Stouffer, 1990) , and that hCG administered in increasing doses at a time consistent with the normal secretion of chorionic gonado¬ trophin results in luteal maintenance (Wilks and Noble, 1983;  Ottobre et al, 1984). Furthermore, these are the first results to show that hCG inhibits the luteolytic effect of PGF2a in vivo, as indicated by augmented progesterone and oestradiol secretion and a prolonged luteal phase. A longer luteal phase supports the observation of Heam and Webley (1987) , who showed that hCG could override the luteolytic action of cloprostenol when co-infused into the corpus luteum of marmosets but not when hCG was administered systemically. A decreased sensitivity of the corpus luteum to an increasing hCG dose over the treatment cycle was also observed, suggesting that over time some modification occurs to the gonadotrophin receptor or to postreceptor events. Initially, however, the corpus luteum is extremely sensitive to very small doses of hCG. Whether the animals were exposed intraluteally to PGF2a or to its vehicle, the most dramatic rise in progesterone (and oestradiol) concen¬ tration was always seen during the first few days of hCG treatment. This was also the case when hCG was administered alone; that is, the corpus luteum responded less to increasing doses of hCG as it aged (Stouffer et al, 1977; Wilks and Noble, 1983) . We confirm the result of Wilks and Noble (1983) ; both progesterone and oestradiol concentrations decrease in the blood before the peak value of hCG occurs.
The observations in this study are also contrary to results in vitro showing that PGF2(I inhibits the action of LH or hCG on progesterone secretion when whole-cell preparations (slices or minces) are used (Stouffer et al, 1979; Dennefors et al, 1982; Patwardhan and Lanthier, 1984) . Studies of dispersed cells did not indicate that PGF2a inhibits hCG-induced progesterone production (Stouffer et al, 1979) , but rather that it has an additive or synergistic action on progesterone production (Richardson and Masson, 1980) . Webley et al (1991) and
Michael and Webley (1991) reported that granulosa luteinized cells obtained by IVF and pretreated with hCG or LH subsequently inhibit the antigonadotrophic effect of cloprost¬ enol, implying a role for protein kinase C. During the admin¬ istration of PGF2a plus hCG, the concentration of progesterone remains high (up to day 15) compared with adding hCG alone or vehicle, also suggesting some additive action of PGF2a on luteal progesterone production; this has also been observed in studies in vitro of the regulation of dispersed human luteal cells (Richardson and Masson, 1980) . To our knowledge, these are the first results showing that the concentration of oestradiol rises in the circulation in response to increasing doses of hCG.
We conclude that the action of intraluteally infused PGF2a, which has been previously shown to induce premature luteal regression, is completely inhibited by concurrent, increasing doses of hCG. The model developed here represents an appropriate system to investigate luteal function as recognized in early pregnancy.
